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258 Dose ﬁnding for the inhalational tobramycin therapy using the
new diaphragm nebulizer I-neb® AAD® System CF
C. Geidel1, K. Weber1, J. Stegemann2, A. Black3, H. Lindemann1, K.P. Zimmer1,
D. Schu¨ler1. 1Center of Pediatrics and Youth medicine, CF-Center, Giessen,
Germany; 2InfectoPharm Arzneimittel und Consilium GmbH, Heppenheim,
Germany; 3Respironics, Tangmere, United Kingdom
The new vibrating mesh technology nebulizer I-neb® AAD® System CF may offer
improvements for the inhalation of anti-pseudomonas therapy for patients with
Cystic Fibrosis (CF). Adaptive Aerosol Delivery (AAD) technology results in a
pre-set dose of medication being delivered to the lung. AAD delivers drug during
the ﬁrst 50−80% inhalation only and the amount of aerosol delivered during each
inhalation phase is dependent upon a patients breathing pattern which is being
analysed throughout their treatment. The amount of medication is adjusted to the
depth and duration of inspiration. With a residual volume of less than 0.1ml, an
efﬁciency of 90% and a 60% fraction of lung deposition (healthy volunteers) the
inhalation therapy is more efﬁcient, may possibly be more cost-saving and may be
done in an acceptable time. The I-neb® AAD® System CF was tested ﬁrst for the
inhalation of Tobramycin with Gernebcin® 80mg/2ml (n = 12). Blood serum levels
were compared with levels after inhalation with compressor and other diaphragm
nebulizers and showed that less medication was needed with I-neb to achieve higher
serum levels compared to the other nebulizers (0.5 mg/ml). This is due to improved
efﬁciency and delivery characteristics of I-neb. A similar Investigation using a
higher dose (160mg/2ml) to determine the optimal applicated dose may offer
a further saving potential. International data refers to necessary serum levels of
1mg/ml 1 h after inhalation. Our current data suggests a required dose of 94mg,
resulting in an inhalation time of about 12min. and reduced medicine consumption.
Supported by: InfectoPharm, Heppenheim, Germany; Respironics, Tangmere, UK.
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Aim: Nebulisation of inhaled drugs has improved in the past years due to
development of new generations of nebulisers, characterized by greater efﬁciency,
portability and shorter nebulisation times. These achievements may improve quality
of life and adherence to therapy in cystic ﬁbrosis (CF) patients. Aim of this study
was to compare in vitro performance of 4 devices [PARI TurboBOY N LC PLUS
(LC), PARI eFlow Rapid (eF), Optineb-ir (Op) and Akita LC Star (Ak)] when
nebulising 4ml of BRAMITOB, a new formulation of inhaled tobramycin developed
by Chiesi Farmaceutici.
Methods: By means of a Next Generation Impactor, the aerodynamic particle
size distribution was studied evaluating the mass median aerodynamic diameter
(MMAD) and ﬁne particle fraction (FPF). Moreover, the Delivered Dose (DD) and
the duration of nebulisation were measured.
Results: The MMAD was lowest with Ak, whereas higher with eF, LC and Op
(2.7mm, 4.1, 4.8 and 5.5mm respectively). The FPF was higher with Ak and eF
(77.3% and 66%) and lower with LC and Op (50.4% and 44.2%). The DD was
similar with eF, LC and Op (86, 81.6 and 87.9mg) but was much higher with Ak
(147.2mg). Nebulisation time was lowest with eF (5.5min) followed by LC and
Op (7.4 and 9.9min respectively), whereas much longer with Ak (24.3min).
Conclusions: Optineb-ir and eFlow Rapid are characterized by an aerodynamic
particle size distribution and a delivered dose similar to that of PARI TurboBOY
N LC PLUS, which is the device used in the clinical trials conducted with
BRAMITOB. However, small differences, such as those observed in the nebulisation
time, may represent an important feature when considered in the daily therapies that
CF patients undergo.
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Introduction: The I-neb® Adaptive Aerosol Delivery (AAD®) System has been
developed to deliver precise, reproducible doses of aerosol into inhalation. We used
a model based on published in vivo data [1] to predict the lung doses from a
conventional jet nebulizer (LC Plus) and the I-neb AAD System using various
ﬁll volumes. An in vitro test was used to verify the delivered doses from both
nebulizers.
Methods: An LC Plus nebulizer was ﬁlled with 2mL salbutamol (5mg/2.5mL)
and run dry using the CEN 500mL simulated breathing pattern. Delivered dose
was collected on a ﬁlter, and analyzed using HPLC. This was repeated in triplicate
for 2.5, 3, 4 and 5mL ﬁll volumes. These tests were repeated using an I-neb device
with equivalent ﬁll volumes, calculated from the model.
Results: As shown in Table 1, the predicted lung dose for the I-neb device
approximated the predicted lung dose for the LC Plus nebulizer. The relationship
between I-neb device and LC Plus nebulizer ﬁll volumes was described by the
equation I-nebﬁll = 0.3586(LCPlusﬁll) − 0.3034.
Conclusion: The I-neb AAD System required less drug to deliver an equivalent
lung dose compared to a conventional jet nebulizer.
Table 1: Fill volumes and calculated lung doses for I-neb AAD System and LC Plus
nebulizer
LC Plus ﬁll volume (mL) 2.0 2.5 3.0 4.0 5.0
LC Plus delivered dose (mL) 429 732 892 1370 1836
Predicted lung dose from LC Plus (mL) 202 344 419 644 863
I-neb ﬁll volume (mL) 0.42 0.65 0.76 1.12 1.47
I-neb delivered dose (mL) 333 577 691 1034 1359
Predicted lung dose from I-neb device (mL) 210 364 435 651 856
Reference(s)
[1] Williams K, et al. Pediatr Pulm. 2007; Suppl 30:355–356.
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The I-neb® Adaptive Aerosol Delivery (AAD®) System has been designed to deliver
precise doses of drug to the patient. The delivered volume is determined either by
the volume of the metering chamber, or by the volume metered into the medication
chamber. We tested the capability of the I-neb AAD System to deliver precise doses of
the ﬁve inhaled medications most commonly used by patients with cystic ﬁbrosis (CF).
Three I-nebs for each drug tested were connected via a ﬁlter to a Harvard pump set
to generate the CEN simulated breathing pattern. For tobramycin 1.5 mL was metered
into the medication chamber, a metering chamber of delivery volume 0.5mL was used
for hypertonic saline and 0.3mL metering chambers were used for the three other
drugs. The expected delivered dose (DD) was calculated by multiplying the metering
chamber delivery volume by the drug concentration. The actual DD was assessed
using a bioassay for colistimethate sodium, HPLC for tobramycin and dornase alfa,
spectrophotometry for salbutamol, and ion analysis for hypertonic saline. Tests were
performed in triplicate for each device/drug combination.
See Table 1 for results. The actual DD approximated the expected DD for each of the
drugs.
Precise doses of colistimethate sodium, dornase alfa, tobramycin, hypertonic saline
and salbutamol sulphate can be delivered into simulated breathing by the I-neb AAD
system.
Table 1. Delivered dose from the I-neb AAD System for 5 drugs used by patients with CF
Drug Metering chamber
delivery volume
Drug concentration Expected
DD
Actual
DD
(SD)
Colistimethate sodium 300mL 1MIU/1mL 300 kIU 324.9 kIU (15.8 kIU)
Dornase alfa 300mL 1mg/1mL 300mg 283.3mg (10.9mg)
Tobramycin 1400mL 60mg/1mL 84mg 75.9mg (6.6mg)
Hypertonic saline 500mL 70mg/1mL 35mg 35.9mg (0.6mg)
Salbutamol sulphate 300 mL 2.0mg/1mL 600mg 605.1mg (10.1mg)
